Inmagene Biopharmaceuticals completes merger with Ikena Oncology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
July 25, 2025 11:00 AM EDTThe combined company will operate under the name ImageneBio, Inc. and will begin trading on Nasdaq under the ticker symbol IMA at market open on Monday, July 28, 2025
ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis
Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Â Inmagene Biopharmaceuticals (Inmagene), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for... More
